FDA Oversight of Drug Imports Scrutinized by House Committee
The top leaders from both parties on the House committee that oversees the Food and Drug Administration have asked that the agency brief the committee staff on its efforts to conduct foreign inspections of facilities that make prescription drugs or…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
the chemicals that go into those drugs that are exported to the U.S. Energy and Commerce Committee Chairman Frank Pallone, Health Subcommittee Chairwoman Anna Eshoo, and Oversight and Investigations Subcommittee Chairwoman Diana DeGette -- along with their Republican counterparts -- sent a letter Feb. 13 to the FDA about their concerns that dangerous drugs could be imported as a consequence of poor oversight of foreign facilities. They noted that a Government Accountability Office report in 2016 found that 1,000 facilities had never been inspected, and that a more recent analysis found 400 still haven't been inspected. The letter also noted the recalls and import alert on a Chinese facility because of contaminants in the drugs it makes, and asked to be briefed on those specific problems.